Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Lansoprazole

Lansoprazole

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Lansoprazole

35 trials tracked of Lansoprazole: 17 in phase 3 or 4 and 8 with published results. The most-cited published study has 317 citations.

35Trials tracked
17Phase 3 & 4
0Recruiting
8With published results
Phase distribution
Phase 4 6 Phase 3 11 Phase 2 4 Phase 1 7 Other / NA 7
  1. Phase 3 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection Completed · 317 cited
  2. Phase 3 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Erosive Esophagitis Completed · 156 cited
  3. Phase 3 Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Participants With Erosive Esophagitis Completed · 155 cited
  4. Phase 4 Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety Completed · 49 cited
  5. Phase 3 Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout Completed · 34 cited
  6. Phase 3 Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis Completed · 14 cited
Show 29 more trials
  1. Phase 3 Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection Completed · 10 cited
  2. Phase 3 Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection Completed · 6 cited
  3. Phase 4 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed
  4. Phase 4 Lansoprazole to Treat Children With Asthma Completed
  5. Phase 4 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed
  6. Phase 4 Treatment of Zollinger-Ellison Syndrome With Prevacid Completed
  7. Phase 4 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors) Completed
  8. Phase 3 Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis Completed
  9. Phase 3 Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis Completed
  10. Phase 3 Efficacy and Safety of Lansoprazole on Gastric and Duodenal Ulcers in Patients Taking Nonsteroidal Anti-Inflammatory Drugs Completed
  11. Phase 3 Efficacy of Lansoprazole in Chronic Post Nasal Drip Completed
  12. Phase 2 Fentanyl Administered Intraorally for Rapid Treatment of Orthopedic Pain Completed
  13. Phase 2 Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment Completed
  14. Phase 2 Proof of Concept Study Efficacy of an Antacid/Lansoprazole Combination for Relief of Heartburn Completed
  15. Phase 2 A Study in Patients With Erosive Esophagitis to Investigate Safety, Tolerability, and Healing Rates After 4 Weeks Treatment of X842 or Lansoprazole and Symptom Pattern During Subsequent 4 Weeks Treatment With Lansoprazole Completed
  16. Phase 1 A Study of LY2940680 in Healthy Participants Completed
  17. Phase 1 Lansoprazole 30 mg DR Capsule Fasting Replicate Sprinkle Study Completed
  18. Phase 1 TAK-438 Bismuth Drug Interaction Study Completed
  19. Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vonoprazan and Lansoprazole in Healthy Participants Completed
  20. Phase 1 A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants Completed
  21. Phase 1 Lansoprazole 30 mg DR Capsule Replicate Food Study Completed
  22. Phase 1 Lansoprazole 30 mg DR Capsule Fasting Study Completed
  23. N/A Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease Completed
  24. N/A Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs Completed
  25. N/A A Clinical Trial of Proton Pump Inhibitors to Treat Children With Chronic Otitis Media With Effusion Completed
  26. N/A Takepron Intravenous 30 mg Specified Drug-use Survey [Acute Stress Ulcer and Acute Gastric Mucosal Lesions] Completed
  27. N/A Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate] Completed
  28. N/A Lansoprazole Tablets Special Drug Use Surveillance Gastroesophageal Reflux Disease With Dyspepsia Symptoms Completed
  29. N/A Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin Completed

Showing the 35 most-cited and recently-updated of 35 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Zastaprazan 20 mg noninferior to lansoprazole 30 mg for gastric ulcer healing at 8 weeks
Drug Pipeline RCT
Zastaprazan 20 mg noninferior to lansoprazole 30 mg for gastric ulcer healing at 8 weeks New medication shows promise for healing gastric ulcers
This Phase 3 randomized, double-blind, active-controlled trial of 329 patients with confirmed gastric ulcers found zastaprazan 20 mg once da…
A new medication called zastaprazan showed a high healing rate for gastric ulcers, performing similarly to the current standard treatment.
Sep 19, 2026
Omeprazole, rabeprazole, pantoprazole, and lansoprazole are associated with increased fracture risk in elderly patients
Drug Pipeline Meta-analysis
Omeprazole, rabeprazole, pantoprazole, and lansoprazole are associated with increased fracture risk in elderly patients Some acid reflux medications may increase fracture risk in seniors
This network meta-analysis of 257,445 patients indicates that omeprazole, rabeprazole, pantoprazole, and lansoprazole are associated with in…
New data suggests that certain acid reflux medications may increase the risk of bone fractures for adults over age 65.
Frontiers Sep 13, 2026